Cargando…
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
BACKGROUND: Metastatic prostate cancer is a clonally heterogeneous disease state characterized by progressive somatic perturbations. The aim of this study was to identify cell free DNA- (cfDNA-) based alterations and their associations with outcomes in progressive metastatic prostate cancer. METHODS...
Autores principales: | Kohli, Manish, Tan, Winston, Zheng, Tiantian, Wang, Amy, Montesinos, Carlos, Wong, Calven, Du, Pan, Jia, Shidong, Yadav, Siddhartha, Horvath, Lisa G., Mahon, Kate L., Kwan, Edmond M., Fettke, Heidi, Yu, Jianjun, Azad, Arun A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186589/ https://www.ncbi.nlm.nih.gov/pubmed/32268276 http://dx.doi.org/10.1016/j.ebiom.2020.102728 |
Ejemplares similares
-
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
por: Mak, Blossom, et al.
Publicado: (2022) -
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
por: Fettke, Heidi, et al.
Publicado: (2023) -
Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
por: Tan, Winston, et al.
Publicado: (2022) -
Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer
por: Kwan, Edmond M., et al.
Publicado: (2021) -
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer
por: Lin, Hui-Ming, et al.
Publicado: (2021)